Oxymetazoline - Allergan

Drug Profile

Oxymetazoline - Allergan

Alternative Names: AGN-199201; Oxymetazoline hydrochloride; Rhofade; V-101

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Vicept Therapeutics
  • Developer Allergan
  • Class Decongestants; Imidazoles; Skin disorder therapies; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Erythema
  • Phase II Presbyopia

Most Recent Events

  • 19 Jan 2017 Registered for Erythema in USA (Topical)
  • 19 Jan 2017 Pooled adverse events and efficacy data from two phase III trials in Erythema released by Allergan
  • 24 May 2016 Allergan expects the PDUFA action date to be in the first half of 2017 for Oxymetazoline for Erythema (Topical, Cream)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top